Fondaparinux

• DVT Prevention
• Pulmonary Embolism Treatment
• Post-Surgical Thromboprophylaxis
• Anticoagulation in HIT

Fondaparinux is a synthetic pentasaccharide anticoagulant that selectively inhibits factor Xa, used for the prevention and treatment of venous thromboembolism. This medication provides predictable anticoagulation with once-daily subcutaneous dosing and does not cause heparin-induced thrombocytopenia.

Mechanism of Action

Fondaparinux is a synthetic pentasaccharide that represents the minimal antithrombin III (AT) binding sequence of heparin. It binds selectively and with high affinity to AT, inducing a conformational change that enhances AT's inhibition of factor Xa by approximately 300-fold. Unlike heparin and low molecular weight heparins, fondaparinux is too short to bridge AT to thrombin, so it has no direct anti-thrombin (anti-IIa) activity. This selective anti-Xa activity results in dose-dependent inhibition of thrombin generation without directly affecting thrombin activity or platelet function. The predictable pharmacokinetics allow for fixed-dose or weight-based dosing without routine monitoring.

Available Formulations

Fondaparinux sodium is available as a solution for subcutaneous injection in single-dose prefilled syringes containing 2.5 mg/0.5 mL, 5 mg/0.4 mL, 7.5 mg/0.6 mL, and 10 mg/0.8 mL. The medication should be stored at room temperature. Each syringe is intended for single use only.

Medical Uses

Fondaparinux is FDA-approved for prophylaxis of DVT in patients undergoing hip fracture surgery, hip replacement surgery, knee replacement surgery, or abdominal surgery at risk for thromboembolic complications; treatment of acute deep vein thrombosis when administered with warfarin; treatment of acute pulmonary embolism when administered with warfarin (in appropriate patients); and treatment of acute superficial vein thrombosis of the legs. It is an alternative to heparin in patients with a history of heparin-induced thrombocytopenia.

Dosing Guidelines

For prophylaxis, 2.5 mg subcutaneously once daily starting 6-8 hours post-surgery, continuing for 5-9 days (up to 32 days for hip fracture surgery). For DVT/PE treatment, weight-based dosing: less than 50 kg: 5 mg; 50-100 kg: 7.5 mg; greater than 100 kg: 10 mg subcutaneously once daily, continued until adequate oral anticoagulation is achieved (minimum 5 days and INR 2-3 for warfarin). The first prophylactic dose should be given no earlier than 6 hours after surgery to reduce bleeding risk.

Important Safety Information

Fondaparinux is contraindicated in patients with severe renal impairment (CrCl less than 30 mL/min) for treatment indications and in patients with body weight less than 50 kg for prophylaxis (increased bleeding risk). It carries a boxed warning for epidural or spinal hematomas in patients receiving neuraxial anesthesia or undergoing spinal puncture. Major bleeding is the primary adverse effect. There is no specific reversal agent; protamine is ineffective. Unlike heparin, fondaparinux does not cause HIT and is an option for patients with HIT history.

Drug Interactions

Drugs that affect hemostasis (anticoagulants, antiplatelet agents, NSAIDs, thrombolytics) increase bleeding risk. Fondaparinux should be discontinued before initiating treatment with other anticoagulants. No significant pharmacokinetic interactions have been identified, as fondaparinux is eliminated primarily renally without metabolism. Routine monitoring with anti-Xa assays is not required but may be helpful in certain populations (renal impairment, extremes of body weight).

Where Fondaparinux Is Chosen Over the Alternatives

Fondaparinux is not a first choice for most clots, and knowing why clarifies when it is the right one. For an uncomplicated first episode of deep venous thrombophlebitis or pulmonary embolism in a patient with adequate kidney function, an oral agent such as apixaban avoids injections entirely, and where an injectable is wanted, enoxaparin is more familiar and more flexible.

Fondaparinux has three distinct advantages. The first and most important is that it does not cause heparin-induced thrombocytopenia, so it is one of the agents reached for in a patient with that history or with the falling platelet count that raises the question, a situation where every form of heparin is off the table and thrombocytopenia is being actively investigated. The second is once-daily dosing, which is easier to sustain than a twice-daily injection over weeks. The third is an approved indication in acute superficial vein thrombosis of the leg, an entity that is often dismissed as trivial but that extends into the deep system often enough to warrant treatment, and for which few other anticoagulants carry labeling. It is also used for thromboprophylaxis after hip fracture and major joint surgery, where the first dose is deliberately delayed for several hours after the operation to limit surgical bleeding, and as the parenteral drug given alongside warfarin until the oral agent reaches range.

No Reversal Agent, and What That Means Day to Day

The absence of an antidote shapes everything practical about this drug. Protamine, which partially reverses heparin, does not work here, and the anticoagulant effect persists for a day or more after the last injection, considerably longer when kidney function is reduced. Nothing about that is dangerous in itself, but it means planning replaces rescue. Any procedure, dental extraction, colonoscopy with anticipated biopsy, or surgery is scheduled with enough lead time to stop the drug in advance, and spinal or epidural anesthesia is not performed without that interval, given the hematoma risk described in the boxed warning. Serious bleeding is managed supportively, with transfusion and local control, rather than with a reversal drug.

Two numbers are confirmed before each new prescription rather than assumed from the chart: kidney function, because the drug is cleared renally and is contraindicated for treatment below the threshold stated above, and body weight, because the treatment dose is banded by weight and because low body weight raises bleeding risk at prophylactic doses. Injection technique mirrors that of other subcutaneous anticoagulants, into the abdominal fat with sites rotated, and the air bubble in the prefilled syringe is left in place. Bruising at the site is expected; bleeding that will not stop, black stools, red or brown urine, or a severe headache is not. The MedlinePlus fondaparinux monograph walks patients through the injection, and the NHLBI overview of venous thromboembolism explains why treatment continues for months after the clot. Patients who travel long distances after a clot will find practical advice in our article on blood clots and snowbird travel, and our hematology team manages the transitions between agents.

Special Populations

Animal studies of fondaparinux showed no fetal harm, but human data are limited. Use during pregnancy only if clearly needed. It is unknown whether fondaparinux is excreted in human breast milk; use caution during breastfeeding. Safety and efficacy have not been established in pediatric patients. Elderly patients may have increased bleeding risk due to age-related renal function decline. The medication is contraindicated for treatment when CrCl is less than 30 mL/min; prophylactic use requires caution with CrCl 30-50 mL/min.